# US 10,500,174 B2 · Pharmaceutical composition for preventing or treating degenerative brain disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,174 B2
- Document ID: US10500174B2
- Status: Granted
- Kind: B2
- Application number: 16/361,129
- Filed: 2019-03-21
- Published: 2019-07-18
- Granted: 2019-12-10
- Earliest claimed: 2016-09-22
- Assignees: Soonchunhyang University Industry Academy Cooperation Foundation
- Applicants: Soonchunhyang University Industry Academy Cooperation Foundation
- Inventors: Jungkyun Im; Goutam Biswas
- Web page: https://patentgrep.com/patent/US10500174B2

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 311/86: Oxygen atoms, e.g. xanthones
- C07D 493/10: Spiro-condensed systems
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2200/322: having an effect on the health of the nervous system or on mental function
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to an ibuprofen conjugate in which ibuprofen (S-(+)-ibuprofen) is covalently linked to a guanidine-terminal-group-bound sugar alcohol derivative and to a pharmaceutical composition containing the same. The ibuprofen conjugate in which ibuprofen is covalently linked to a guanidine-terminal-group-bound sugar alcohol derivative can more effectively penetrate into the brain by passing through the blood-brain barrier (BBB), thus enabling efficient drug delivery to the brain, whereby administration of the ibuprofen conjugate in an optimal dose can minimize side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and can prevent or treat degenerative brain disease.

## Claims

### Claim 1

A pharmaceutical composition for treating a brain disease, containing, as an active ingredient, a compound represented by Chemical Formula 1 below:
wherein X is represented by Chemical Formula 2 below:
wherein the R groups are selected from the group consisting of hydrogen, deuterium or Chemical Formula 3 below:
wherein at least one R is Chemical Formula 3, and FITC represents a fluorescein group.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein all of the R groups are represented by Chemical Formula 3.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the brain disease is selected from the group consisting of stroke, palsy, dementia, Alzheimer's disease, Parkinson's disease, Lou Gehrig's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, thrombosis, embolism, transient ischemic attack, lacune, multiple sclerosis, proximal lateral sclerosis, palsy, stroke, mild cognitive impairment, cerebral hemorrhage, cerebral infarction, head trauma, cerebral circulation metabolic disorder, and brain coma.

### Claim 4

A compound represented by Chemical Formula 1 below:
wherein X is represented by Chemical Formula 2 below:
wherein the R groups are selected from the group consisting of hydrogen, deuterium or Chemical Formula 3 below:
wherein at least one R is chemical formula 3, and FITC represents a fluorescein group.

### Claim 5 (depends on 4)

The compound of claim 4, wherein all of the R groups are represented by Chemical Formula 3.

### Claim 6 (depends on 4)

A health functional food composition for treating a degenerative brain disease, comprising the compound of claim 4.